New packaging for Regeneron monoclonal antibodies

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jgold@ismp.org. 

1 post / 0 new
Log in or register to post comments
Fri, 02/05/2021 - 06:54
#1
Mike Cohen
Mike Cohen's picture
Offline
Last seen: 2 months 1 week ago
Joined: 06/08/2014 - 19:54
New packaging for Regeneron monoclonal antibodies

Regeneron received FDA approval yesterday for unit of use packaging for their casirivimab and indevimab monoclonal antibodies. New EUA labeling includes the nonproprietary names for each (previously labeled as investigational new drugs) as well as functioning bar codes.

The packaging changes address many of the issues that ISMP called to the company's attention in December (https://ismp.org/resources/handling-monoclonal-antibodies-lilly-and-rege...) and again last month (https://ismp.org/resources/learning-errors-new-covid-19-vaccines).

The new labeling and the packaging configurations can be found here:
https://www.regeneron.com/sites/default/files/treatment-covid19-eua-prev....

Thanks to all of you who reported issues with Lilly and Regeneron monoclonals. FDA and manufacturers are listening.

Mike

Tags: 

Top